Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the RIBBON-2 trial

Breast Cancer Research and Treatment

Volumn 133, Issue 3, 2012, Pages 1067-1075

  Brufsky, Adam ^a   Valero, Vicente ^b   Tiangco, Beatrice ^c   Dakhil, Shaker ^d   Brize, Arija ^e   Rugo, Hope S ^f   Rivera, Ragene ^g   Duenne, Anja ^h   Bousfoul, Naima ^h   Yardley, Denise A ^i,j  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c PHILIPPINE GENERAL HOSPITAL   (Philippines)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j Tennessee Oncology PLLC   (United States)

more..

Author keywords

Angiogenesis; Bevacizumab; Metastatic breast cancer; Second line chemotherapy; Triple negative breast cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; GEMCITABINE; NAVELBINE; PLACEBO; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; BREAST METASTASIS; CANCER GROWTH; CANCER PATIENT; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METABOLIC ACIDOSIS; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUDDEN DEATH; SURVIVAL RATE; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863719309     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2008-6     Document Type: Article

References (19)

1. Gluz O, Liedtke C, Gottschalk N et al (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20:1913-1927
2. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429-4434
3. Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767
4. O'Shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214
5. O'Shaughnessy J, Schwartzberg LS, Danso MA et al. (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29(Suppl): Abstract 1007
6. O'Shaughnessy J, Dieras V, Glaspy J et al. (2009) Comparison of subgroup analyses of PFS from three phase III studies of bev-acizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 69(Suppl):512s (Abstract 207)
7. Gray R, Bhattacharya S, Bowden C et al (2009) Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972
8. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus doce-taxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247
9. Robert N, Dieras V, Glaspy G et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally-recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260
10. Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286-4293
11. Greenberg S, Rugo H (2010) Triple-negative breast cancer: role of antiangiogenic agents. Cancer J 16:33-38
12. Rydén L, Jirström K, Haglund M, Stål O, Fernö M (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 120:491-498
13. Smith IE, Pierga J-Y, Biganzoli L et al (2011) Final overall survival results and effect of prolonged (C1 year) first-line bev-acizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 130:133-143
14. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus cape-citabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799
15. Baselga J, Stemmer SM, Pego A et al. (2010) Cetuximab? cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 70(24 Suppl):95s (Abstract PD01-01)
16. TM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol 21(Suppl 8): viii5 (Abstract LBA12)
17. Roché HH, Sparano J, Valero V et al. (2010) Ixabepilone (IXA) and capecitabine (C) in patients (pts) with triple-negative breast cancer (TNBC): a retrospective analysis of phase 2 and phase 3 clinical studies. Ann Oncol 21(Suppl 8):viii103 (Abstract 299P)
18. Irvin WY, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44:2799-2805
19. Prat A, Parker JS, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68